PDLIM7 and cervical cancer: A well-executed retrospective cohort study contributes to our understanding of the prevalence of EBV by targeting EBNA-1 and LMP-1 in cervical cancer specimens, with the authors reporting a 22.2% prevalence (n = 22) in their cohort of 99 patients.